{"created":"2021-03-01T06:11:02.514916+00:00","id":7193,"links":{},"metadata":{"_buckets":{"deposit":"844093fc-49a4-4ef7-a8c6-78c5d5f2dcc5"},"_deposit":{"id":"7193","owners":[],"pid":{"revision_id":0,"type":"depid","value":"7193"},"status":"published"},"_oai":{"id":"oai:soar-ir.repo.nii.ac.jp:00007193","sets":["461:848:849"]},"author_link":["17449","17450","17451","17452","17453","17454","17455"],"item_1628147817048":{"attribute_name":"出版タイプ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_6_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2012","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"12","bibliographicPageEnd":"1500","bibliographicPageStart":"1493","bibliographicVolumeNumber":"51","bibliographic_titles":[{"bibliographic_title":"INTERNAL MEDICINE"}]}]},"item_6_description_19":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"信州大学博士（医学）・学位論文・平成24年3月31日授与（甲第914号）・内藤康介","subitem_description_type":"Other"}]},"item_6_description_20":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background Neuralgic amyotrophy (NA) is a distinct peripheral nervous system disorder characterized by attacks of acute neuropathic pain and rapid multifocal weakness and atrophy unilaterally in the upper limb. The current hypothesis is that the episodes are caused by an immune-mediated response to the brachial plexus, however, therapeutic strategies for NA have not been well established. Methods and Results We retrospectively reviewed 15 case series of NA; 10 of the 15 patients received intravenous immunoglobulin (IVIg) with methylprednisolone pulse therapy (MPPT) and 9 of these10 patients showed clinical improvement of motor impairment. Conclusion Our clinical observations do not contradict the possibility that IVIg with MPPT may be one of the potential therapeutics for NA, however the efficacy remains to be established. Further confirmatory trials are needed in patients with various clinical severities and phases of NA. Further basic research and confirmatory trials should be performed to survey the efficacy of such immunomodulation therapy for NA.","subitem_description_type":"Abstract"}]},"item_6_description_30":{"attribute_name":"資源タイプ（コンテンツの種類）","attribute_value_mlt":[{"subitem_description":"Article","subitem_description_type":"Other"}]},"item_6_description_5":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"INTERNAL MEDICINE. 51(12):1493-1500 (2012)","subitem_description_type":"Other"}]},"item_6_link_3":{"attribute_name":"信州大学研究者総覧へのリンク","attribute_value_mlt":[{"subitem_link_text":"Morita, Hiroshi","subitem_link_url":"http://soar-rd.shinshu-u.ac.jp/profile/ja.HUyNHhkh.html"}]},"item_6_link_67":{"attribute_name":"WoS","attribute_value_mlt":[{"subitem_link_text":"Web of Science","subitem_link_url":"http://gateway.isiknowledge.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=ShinshuUniv&SrcApp=ShinshuUniv&DestLinkType=FullRecord&DestApp=WOS&KeyUT=000305968100007"}]},"item_6_publisher_4":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"JAPAN SOC INTERNAL MEDICINE"}]},"item_6_relation_47":{"attribute_name":"PubMed","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"22728480"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=pubmed&term=22728480","subitem_relation_type_select":"PMID"}}]},"item_6_relation_48":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"10.2169/internalmedicine.51.7049"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.2169/internalmedicine.51.7049","subitem_relation_type_select":"DOI"}}]},"item_6_source_id_35":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0918-2918","subitem_source_identifier_type":"ISSN"}]},"item_6_source_id_40":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AA10827774","subitem_source_identifier_type":"NCID"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Naito,  Ko-suke"}],"nameIdentifiers":[{"nameIdentifier":"17449","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Fukushima,  Kazuhiro"}],"nameIdentifiers":[{"nameIdentifier":"17450","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Suzuki,  Seiko"}],"nameIdentifiers":[{"nameIdentifier":"17451","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kuwahara,  Motoi"}],"nameIdentifiers":[{"nameIdentifier":"17452","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Morita,  Hiroshi"}],"nameIdentifiers":[{"nameIdentifier":"17453","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kusunoki,  Susumu"}],"nameIdentifiers":[{"nameIdentifier":"17454","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ikeda,  Shu-ichi"}],"nameIdentifiers":[{"nameIdentifier":"17455","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2015-09-25"}],"displaytype":"detail","filename":"H23Kou914_Naito.pdf","filesize":[{"value":"233.1 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"H23Kou914_Naito.pdf","url":"https://soar-ir.repo.nii.ac.jp/record/7193/files/H23Kou914_Naito.pdf"},"version_id":"32196de3-f444-4ca4-b4ca-29bf63e5ed0b"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"neuralgic amyotrophy","subitem_subject_scheme":"Other"},{"subitem_subject":"intravenous immunoglobulin","subitem_subject_scheme":"Other"},{"subitem_subject":"methylprednisolone pulse therapy","subitem_subject_scheme":"Other"},{"subitem_subject":"Parsonage-Turner syndrome","subitem_subject_scheme":"Other"},{"subitem_subject":"brachial plexus","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Intravenous Immunoglobulin (IVIg) with Methylprednisolone Pulse Therapy for Motor Impairment of Neuralgic Amyotrophy: Clinical Observations in 10 Cases","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Intravenous Immunoglobulin (IVIg) with Methylprednisolone Pulse Therapy for Motor Impairment of Neuralgic Amyotrophy: Clinical Observations in 10 Cases","subitem_title_language":"en"}]},"item_type_id":"6","owner":"1","path":["849"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2012-10-02"},"publish_date":"2012-10-02","publish_status":"0","recid":"7193","relation_version_is_last":true,"title":["Intravenous Immunoglobulin (IVIg) with Methylprednisolone Pulse Therapy for Motor Impairment of Neuralgic Amyotrophy: Clinical Observations in 10 Cases"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2022-12-14T03:54:09.556796+00:00"}